Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 14Active not recruiting 6Not yet recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Multiple Myeloma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Specimen Handling 21Magnetic Resonance Spectroscopy 17Carboplatin 16Gemcitabine 14pembrolizumab 11Paclitaxel 11Cisplatin 11Interviews as Topic 10Injections 10fludarabine 9Radiotherapy 8Oxaliplatin 8Nivolumab 8Dexamethasone 8Cyclophosphamide 8Irinotecan 7Fluorouracil 7Bortezomib 7Biopsy 7Bevacizumab 7toripalimab 6Radiosurgery 5Pemetrexed 5Leucovorin 5Capecitabine 5130-nm albumin-bound paclitaxel 5trastuzumab deruxtecan 4liposomal doxorubicin 4cemiplimab 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × pomalidomide × 30 days × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT07609446 2026-05-27

Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma

The First Affiliated Hospital of Soochow University

Not yet recruiting
30 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡